Melinta's Baxdela passes second Phase III test

Melinta Therapeutics Inc. (New Haven, Conn.) said IV-to-oral Baxdela delafloxacin (RX-3341) was non-inferior to the standard-of-care regimen of vancomycin plus aztreonam, meeting the primary

Read the full 242 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE